Compare ZSTK & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZSTK | COCP |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 21.6M |
| IPO Year | 2023 | 2011 |
| Metric | ZSTK | COCP |
|---|---|---|
| Price | $4.84 | $1.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.3M | 52.9K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.65 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,676,000.00 | $12,712,091.00 |
| Revenue This Year | $15.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.32 | $0.76 |
| 52 Week High | $12.40 | $2.03 |
| Indicator | ZSTK | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 58.54 | 64.59 |
| Support Level | $4.76 | $1.17 |
| Resistance Level | $5.39 | $1.59 |
| Average True Range (ATR) | 0.98 | 0.07 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 32.52 | 68.47 |
ZeroStack Corp is an AI focused asset management company. The company also operates a world-wide Commercial and wholesale business through its wholly owned subsidiary. ZeroStack is focused on providing exposure to decentralized AI through a concentrated digital asset approach structured to generate yield and fee-based income from staking validators, compute power technology companies, and complementary businesses within the ecosystem and across the wider AI landscape. The other segment commercial and wholesale (Phatebo and TruHC), which sell pharmaceutical products and mix of products across multiple categories including food and beverage, cannabis accessories and technology, personal care and wellness.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.